her2-

ORIC Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

December 05, 2025 01:00 ET  | Source: ORIC Pharmaceuticals Systemic activity of 35% ORR in 2L+ patients, including in patients…

1 day ago